Immunic, inc. reports third quarter 2024 financial results and provides corporate update

– positive interim analysis of phase 3 ensure program, unblinded independent data monitoring committee confirmed that predetermined futility criteria have not been met and recommended trials should continue as planned – – ongoing, twin phase 3 ensure trials in relapsing multiple sclerosis and phase 2 calliper trial in progressive multiple sclerosis remain on track  – – top-line data from phase 2 calliper trial expected in april 2025 – – webcast to be held today, november 7, at 8:00 am et – new york , nov. 7, 2024 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the third quarter and nine months ended september 30, 2024, and provided a corporate update. "during the third quarter, we have continued to advance both our phase 2 calliper trial in patients with progressive multiple sclerosis (pms) and our twin phase 3 ensure trials in relapsing multiple sclerosis (rms), for our potentially transformative, orally available lead asset, nuclear receptor related 1 (nurr1) activator, vidofludimus calcium (imu-838)," stated daniel vitt, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking